HIV and SARS-CoV-2 Co-Infection: From Population Study Evidence to In Vitro Studies

Abstract

Human immunodeficiency virus type 1 (HIV-1) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have caused two major viral outbreaks during the last century. Two major aspects of HIV-1 and SARS-CoV-2 co-infection have been extensively investigated and deserve attention. First, the impact of the co-infection on the progression of disease caused by HIV-1 or SARS-CoV-2. Second, the impact of the HIV-1 anti-retroviral treatment on SARS-CoV-2 infection. In this review, we aim to summarize and discuss the works produced since the beginning of the SARS-CoV-2 pandemic ranging from clinical studies to in vitro experiments in the context of co-infection and drug development.

Pseudotyped Viruses As a Molecular Tool to Monitor Humoral Immune Responses Against SARS-CoV-2 Via Neutralization Assay

“…SARS-CoV-2 is a highly pathogenic human Betacoronavirus, identified for the first time in China (Wu Han) which became rapidly pandemic, causing more than 6 million deaths worldwide 23,24 . Because of the validation of vaccine strategies, the pandemic has been largely controlled; nonetheless, in most vulnerable people, such as cancer patients or people living with HIV, it does still pose a risk [25][26][27] . In this context, there is still a need for validated assays to monitor the antivaccine humoral response in terms of neutralizing activity.…”